Skip to content

Voxeleron Appoints New CEO and Secures Funding to Continue Growing Its Innovative Ophthalmic Image Analysis Platform

Seasoned life science industry veteran to drive the next phase of growth and market expansion AUSTIN, TX – March 13, 2024: Voxeleron, a cloud-based ophthalmic image analysis platform provider, today announced the appointment of Joanna Williams as its new Chief Executive Officer (CEO). With over 25 years of experience in…

Read more

Voxeleron is ISO 13485:2016 Certified

Voxeleron is now ISO 13485:2016 certified. This key accomplishment, complementing our existing SOC 2 certification and compliance to 21 CFR Part 11 and GDPR, reflects our commitment to quality in the development and delivery of our platform and services, and underlines our priority of data security, traceability and privacy. ISO…

Read more

Emerging Trends in HealthTech and Ophthalmology: Key Insights from MedTech 2023

MedTech recently held its annual conference, showcasing the latest developments in the HealthTech market. Among the key takeaways were pivotal trends influencing the industry, shedding light on the crucial aspects that will redefine patient care, data privacy, collaboration, and the integration of artificial intelligence in healthcare. Navigating Ethical Gray Areas…

Read more

Three Headaches in Ophthalmic Research You Can Avoid with Orion by Voxeleron

Three Headaches in Ophthalmic Research You Can Avoid with Orion by Voxeleron In the world of ophthalmic research and clinical trials, efficiency and accuracy are paramount to successful outcomes. As trials navigate through diverse image modalities and file formats, tackle time-consuming reads, and grapple with inflexible proprietary platforms, a solution…

Read more

The Download from ARVO 2023: AI and Interoperability Drive Breakthroughs in Ophthalmic Research

The Download from ARVO 2023: AI and Interoperability Drive Breakthroughs in Ophthalmic Research The American Association for Research in Vision and Ophthalmology (ARVO) recently held its annual conference, showcasing the latest developments in the industry. Among the key takeaways were the crucial roles of artificial intelligence (AI) and interoperability in…

Read more

Voxeleron at ARVO 2023

Voxeleron at ARVO 2023 An ARVO in April in New Orleans is certainly an exciting prospect, so we look forward to our time in this historic city.   Ahead of that, we’re taking the opportunity to share some updates as a year is a long time in the world of…

Read more

Orion vs. Cirrus vs. Spectralis

In order to fulfill recruitment goals, large clinical trials must necessarily use images from numerous sites utilizing different imaging vendor systems. For OCT images, limitations in image segmentation with the original equipment manufacturer (OEM) software and differences between the algorithms used by the different OEM software programs can introduce bias…

Read more

A Growing IP Portfolio in Further Support of Reading Center Workflows

Within the context of clinical trials, the analysis of optical coherence tomography (OCT) images can be a time consuming process.  Data files that can be as large as a Gigabyte must be moved around, anonymized and loaded into different analysis tools depending on the format.  Once segmented, the boundaries of…

Read more

SOC 2 & 21 CFR Part 11 Announcement

SOC 2 & 21 CFR Part 11 Announcement Voxeleron is now SOC 2 Type 1 certified and in compliance with FDA’s 21 CFR Part 11. Taking excellent care of customer data is our highest priority, and we are invested in implementing security measures that follow all clinical research standards. Achieving…

Read more

Fluid Quantification in OCT – A Validation using a Home-Based OCT Device

Voxeleron’s AI Retinal Fluid Quantification Highlighted in Retina Voxeleron is pleased to announce the publication in Retina of our most recent validation paper on AI-based fluid quantification.  In this case it is using the RetinaCheck low-cost optical coherence tomography (OCT) device (OCTHealth LLC, Sacramento, California).  This prospective study was based…

Read more